238 related articles for article (PubMed ID: 10531185)
21. The role of treprostinil in the management of pulmonary hypertension.
Skoro-Sajer N; Lang I
Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755
[TBL] [Abstract][Full Text] [Related]
22. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
Badesch DB; McGoon MD; Barst RJ; Tapson VF; Rubin LJ; Wigley FM; Kral KM; Raphiou IH; Crater GD
J Rheumatol; 2009 Oct; 36(10):2244-9. PubMed ID: 19723905
[TBL] [Abstract][Full Text] [Related]
23. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
24. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
Cabrol S; Souza R; Jais X; Fadel E; Ali RH; Humbert M; Dartevelle P; Simonneau G; Sitbon O
J Heart Lung Transplant; 2007 Apr; 26(4):357-62. PubMed ID: 17403477
[TBL] [Abstract][Full Text] [Related]
25. Pulmonary edema during acute infusion of epoprostenol in a patient with pulmonary hypertension and limited scleroderma.
Farber HW; Graven KK; Kokolski G; Korn JH
J Rheumatol; 1999 May; 26(5):1195-6. PubMed ID: 10332990
[TBL] [Abstract][Full Text] [Related]
26. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension.
Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R
Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444
[TBL] [Abstract][Full Text] [Related]
27. Moderate-term effect of epoprostenol on severe portopulmonary hypertension.
Kato H; Katori T; Nakamura Y; Kawarasaki H
Pediatr Cardiol; 2003; 24(1):50-3. PubMed ID: 12574979
[TBL] [Abstract][Full Text] [Related]
28. Massive pulmonary edema and death after prostacyclin infusion in a patient with pulmonary veno-occlusive disease.
Palmer SM; Robinson LJ; Wang A; Gossage JR; Bashore T; Tapson VF
Chest; 1998 Jan; 113(1):237-40. PubMed ID: 9440597
[TBL] [Abstract][Full Text] [Related]
29. Echocardiographic assessment of pulmonary hypertension in Gaucher's disease.
Elstein D; Klutstein MW; Lahad A; Abrahamov A; Hadas-Halpern I; Zimran A
Lancet; 1998 May; 351(9115):1544-6. PubMed ID: 10326537
[TBL] [Abstract][Full Text] [Related]
30. Continuous infusion of epoprostenol improves the net balance between pulmonary endothelin-1 clearance and release in primary pulmonary hypertension.
Langleben D; Barst RJ; Badesch D; Groves BM; Tapson VF; Murali S; Bourge RC; Ettinger N; Shalit E; Clayton LM; Jöbsis MM; Blackburn SD; Crow JW; Stewart DJ; Long W
Circulation; 1999 Jun; 99(25):3266-71. PubMed ID: 10385501
[TBL] [Abstract][Full Text] [Related]
31. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
[TBL] [Abstract][Full Text] [Related]
32. Successful epoprostenol withdrawal in pulmonary arterial hypertension: case report and literature review.
Demerouti EA; Manginas AN; Athanassopoulos GD; Karatasakis GT; Leontiadis ED; Pavlides GS
Respir Care; 2013 Feb; 58(2):e1-5. PubMed ID: 22710078
[TBL] [Abstract][Full Text] [Related]
33. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
34. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension.
Gomberg-Maitland M; Tapson VF; Benza RL; McLaughlin VV; Krichman A; Widlitz AC; Barst RJ
Am J Respir Crit Care Med; 2005 Dec; 172(12):1586-9. PubMed ID: 16151039
[TBL] [Abstract][Full Text] [Related]
35. Low incidence of catheter-related complications in patients with advanced pulmonary arterial hypertension undergoing continuous epoprostenol infusion.
Nagai T; Kohsaka S; Anzai T; Yoshikawa T; Fukuda K; Sato T
Chest; 2012 Jan; 141(1):272-273. PubMed ID: 22215838
[No Abstract] [Full Text] [Related]
36. Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery.
Bildirici I; Shumway JB
Obstet Gynecol; 2004 May; 103(5 Pt 2):1102-5. PubMed ID: 15121623
[TBL] [Abstract][Full Text] [Related]
37. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
[TBL] [Abstract][Full Text] [Related]
38. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
Suleman N; Frost AE
Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
[TBL] [Abstract][Full Text] [Related]
39. Ondansetron eliminates nausea and vomiting associated with prostacyclin in a patient awaiting lung transplantation.
Lawhorn S; Lawhorn CD; Davison C
J Heart Lung Transplant; 1997 Apr; 16(4):472-3. PubMed ID: 9154961
[No Abstract] [Full Text] [Related]
40. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension.
Barst RJ; Rubin LJ; Long WA; McGoon MD; Rich S; Badesch DB; Groves BM; Tapson VF; Bourge RC; Brundage BH; Koerner SK; Langleben D; Keller CA; Murali S; Uretsky BF; Clayton LM; Jöbsis MM; Blackburn SD; Shortino D; Crow JW;
N Engl J Med; 1996 Feb; 334(5):296-301. PubMed ID: 8532025
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]